Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 3/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR1B | P28222 | 2/20 | 0.41 |
| ▸ | NCF1 | P14598 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532160 | 0.85 | HTR1D (0.44) | HCRTR1HCRTR2HTR1DHRH3TLR9 | |
| SCHEMBL5532963 | 0.85 | NCF1 (0.58) | HTR1DHRH3HTR1AHTR1BNCF1 | |
| SCHEMBL5532322 | 0.84 | SLC2A1 (0.45) | ADAM17HCRTR1HCRTR2HTR1DHRH3 | |
| SCHEMBL5537578 | 0.83 | HTR1A (0.53) | ADAM17HTR1DHRH3HTR1AHTR1B | |
| SCHEMBL5527371 | 0.83 | HTR1D (0.49) | ADAM17HCRTR1HCRTR2HTR1DHRH3 | |
| SCHEMBL5528217 | 0.83 | HRH3 (0.52) | HCRTR1HCRTR2HRH3HTR1ANCF1 | |
| SCHEMBL14437441 | 0.81 | NCF1 (0.51) | ADAM17HTR1DTLR9TLR8TLR7 | |
| SCHEMBL5529815 | 0.81 | NCF1 (0.51) | HTR1DHTR1AHTR1BNCF1 | |
| SCHEMBL5532956 | 0.81 | MCHR1 (0.53) | HCRTR1HCRTR2HTR1DHTR1AHTR1B | |
| SCHEMBL5529129 | 0.80 | HTR1D (0.52) | HTR1DHTR1AHTR1BNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | ADAM17 3125/4885HCRTR1 887/4885HCRTR2 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.